Abstract
Gastroesophageal reflux disease (GERD) and anxiety/depression are common comorbidities in patients with severe eosinophilic asthma; they add to disease burden and may influence treatment responses. We evaluated real-world mepolizumab effectiveness in patients with these comorbidities.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
